Background: Gastrectomy remains a major operation with potential for significant deterioration in patients' health-related quality of life (QOL). This study assessed differences in QOL among patients after distal (DG), proximal (PG), or total (TG) gastrectomy. Methods: We prospectively enrolled patients undergoing gastrectomy at our institution between 2002 and 2007. Participants completed the European Organization for Research and Treatment of Cancer cancer (QLQ-C30) and gastric (QLQ-STO22) questionnaires preoperatively and at 5 postoperative intervals up to 18 months. We compared changes from baseline in patients based on extent of resection (proximal, distal, or total) using generalized linear models, adjusting for age, stage of disease, and (neo)adjuvant therapy. We converted QOL raw scores to reflect the proportion of patients with clinically significant deterioration based on the minimal important difference. Results: We included 134 patients: 82 DG, 16 PG, and 36 TG. In the immediate postoperative period, 55% of patients suffered significant impairment in their global QOL. This improved in most patients by 6 months, although 20% to 35% continued to have substantially worse QOL than before surgery. Patients who underwent PG suffered from significantly more clinical reflux [70% vs 35% (DG), 40% (TG)], nausea/vomiting (60% vs 25%, 30%), and global QOL impairment (60% vs 30%, 30%) than patients who underwent DG or TG, whose QOL scores were similar. These differences persisted up to 18 months postoperatively. Conclusions: Surgeons should discuss expectations of QOL impairment with their patients before gastrectomy and reassure them that most symptoms resolve by 6 months after operation. Patients who undergo PG suffer from worse QOL impairment than patients who undergo DG or TG.
For tumors located in the lower half of the stomach, distal gastrectomy (DG) is the procedure of choice. For tumors in the upper half of the stomach, proximal gastrectomy (PG) or total gastrectomy (TG) is needed to achieve adequate surgical margins. Researchers have attempted to determine the relationship between the extent of gastric resection and the severity of postoperative symptoms, reaching varied conclusions. [4] [5] [6] [7] [8] [9] These studies have suffered from important limitations that make interpretation difficult, most importantly small sample sizes and retrospective study designs. We sought to prospectively explore the impact of surgical resection on QOL after resection of gastric cancer in a large group of patients.
METHODS

Patients
We screened all patients with gastric cancer assessed by surgeons at our institution between November 15, 2002 and June 15, 2007 for enrollment in this prospective cohort study. Memorial Sloan-Kettering Cancer Center is a major comprehensive cancer center with a large program in gastric cancer. Patients were eligible for the study if they were older than 18 years of age, underwent a gastric resection for adenocarcinoma, and were deemed psychologically capable of completing the QOL questionnaires. We excluded patients who were receiving active treatment of a concurrent nongastric cancer. This study was approved by the institutional review board and all patients signed an informed consent form before beginning the study.
Interventions
Patients were treated according to our institutional practices for patients with gastric cancer. Briefly, patients undergo staging investigations, including computed tomography, endoscopic ultrasonography, and/or laparoscopy. Patients with locally advanced gastric cancer are usually treated with induction chemotherapy followed by resection and postoperative chemotherapy, whereas patients with early gastric cancer proceed directly to resection. Patients with metastatic disease undergo resection only for palliation of symptoms.
Surgical procedures were classified as DG if they included the distal stomach and pylorus but not the esophagogastric (junction, PG if they included the proximal stomach and esophagogastric junction but not the distal stomach, and TG if the entire stomach was resected. Patients who had wedge resections were not included in this study. Reconstruction was performed with Billroth II gastrojejunostomy after DG, esophagogastrostomy after PG, and Roux-en-Y esophagojejunostomy after TG. functional scales (Physical, Role, Emotional, Cognitive, and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are monoitem scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, and financial difficulties).
The gastric cancer module (QLQ-STO22) is a supplement to the QLQ-C30 intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation, or palliative chemotherapy. The QLQ-STO22 consists of 22 questions that evaluate 5 multi-item symptoms scales (dysphagia, eating restrictions, pain, reflux, and anxiety), and 4 single-item symptoms scales (dry mouth, body image, hair loss, and taste loss). For global QOL and the functional scales, a higher score indicates better QOL, with 100 being perfect. For symptom scales, a lower score indicates better QOL, with 0 being perfect or no symptoms reported.
Patients completed the QLQ-C30 and the STO22 questionnaires preoperatively, postoperatively, and at 4 other postoperative time intervals: 3, 6, 12, and 18 months after resection.
Statistical Analyses
For each subscale of the QLQ-C30 and QLQ-STO22, we compared changes from baseline in patients on the basis of the type of resection (proximal, distal, or total) using generalized linear models including time of assessment and type of resection. In addition, we computed the area under the QOL-time profile for each patient and used this as a single-number summary for supplemental analysis. To account for informative dropouts, we used a pattern-mixture model, stratifying all analyses by the dropout time. We excluded patients with less than 2 follow-up points from this analysis. We performed adjusted analyses, including age, treatment (chemotherapy and/or radiation), and stage of disease in the model. All statistical analyses were performed with SAS version 9.2.
To make the statistically significant results more meaningful to clinicians and patients, we converted the QOL scores to reflect the proportion of patients with a clinically significant deterioration in each domain. For each domain of the QLQ-C30 and QLQ-STO22, we calculated the minimal important difference (MID), defined as the smallest change that patients perceive as important. [12] [13] [14] [15] Although investigators have identified clinical thresholds specific for the QLQ-C30, no such anchors exist for the QLQ-STO22. We therefore defined the MID for each domain using the conventional approach of an effect size greater than 0.5, which empirically yields nearly identical values to the clinical interpretation of a "moderate difference." 16, 17 Because there was no control group in this study, we used the pooled standard deviation of the baseline scores for each group to calculate the MID. We determined the proportion of patients in each group that experienced a change in quality-of-life equal to or greater than the MID at each time point.
RESULTS
Four hundred seventy-five patients were identified as candidates for surgical resection, of whom 209 consented for entry into the study ( Fig. 1 ). Of these, 29 patients were unresectable and 10 were excluded for other reasons, leaving 170 patients entered into this study. During the 18-month study period, 56 patients (33%) died. Data from 2 or more postoperative time points were available from 134 of the 157 alive patients (85%), and complete questionnaires were collected at all intervals from 86 of the possible 114 patients (75%). Table 1 presents demographic characteristics of the study participants. Most patients had early-stage disease and approximately 50% of patients received some form of adjuvant or neoadjuvant therapy. DG was most commonly performed, followed by TG and PG.
In the immediate postoperative period, 50% to 70% of patients suffered a significant impairment in their global QOL, physical func- tion, and role function (Fig. 2 ). Symptoms improved in most patients by 6 months, although 20% to 35% continued to have substantially worse function in these domains even at 18 months postoperatively. Similar trends were observed in patients' complaints of pain and fatigue, whereas nausea and vomiting was a concern to 35% of patients postoperatively and remained relatively constant over time. Dysphagia, appetite loss, and eating restrictions were the most common disease-specific symptoms, occurring in 45% to 55% of patients in the immediate postoperative period (Fig. 3 ). These symptoms improved by 6 months in most patients but persisted in approximately 20% to 30% of patients.
In multivariable analyses, statistically significant differences were seen on the basis of extent of gastrectomy in global QOL, reflux, diarrhea, and nausea/vomiting ( Table 2) . Patients who underwent PG suffered from significantly more reflux [70% vs 35% (DG), 40% (TG)], nausea/vomiting (60% vs 25%, 30%), and global QOL impairment (60% vs 30%, 30%) than patients who underwent DG or TG, whose QOL scores were similar (Fig. 4 ). These differences persisted from the immediate postoperative period to 18 months from operation. In contrast, more patients who underwent TG complained of diarrhea than patients who underwent DG or PG (40% vs 25%, 20%).
DISCUSSION
This prospective study including 134 patients undergoing gastric resection for adenocarcinoma identifies many findings that surgeons can apply to clinical care. As part of the informed consent process, surgeons should discuss with patients how they might rea-sonably expect to feel in the postoperative period. Conventionally, this has been done using vague, qualitative terms. This study provides quantitative measures of QOL that surgeons and patients can easily understand and incorporate into the decision-making process.
In the immediate postoperative period, the majority of patients suffer from important impairment in global QOL. At the time of the first follow-up visit, 60% to 70% of patients can expect to feel fatigued, with worse overall function and QOL than preoperatively. Surgeons can reassure patients that most will return to baseline function by approximately 6 months postoperatively, although about a third of patients will continue to have important functional impairment. In contrast, only a third of patients will ever suffer symptoms, such as reflux, nausea, and dry mouth, although these symptoms will generally persist through follow-up.
The differing QOL between patients based on extent of gastrectomy may help surgeons select the optimal resection for some patients. For patients with tumors localized in the distal stomach, DG allows resection of gross disease. For patients with proximal tumors, resection with clear margins may be achieved with PG or TG. For patients with extensive malignancies, subtotal or total gastrectomy may be needed to achieve clear margins. Although these operative approaches seem to be oncologically equivalent for appropriate tumors, 18 each approach on QOL differs and should help direct surgical practice. In this analysis, the QOL after TG was almost identical in all domains to the QOL after DG. In contrast, patients who underwent PG suffered from significantly more reflux, nausea/vomiting, and a worse overall QOL. The improved global QOL of patients who underwent TG compared with patients who underwent PG suggests that PG may not be the optimal procedure for most patients with tumors localized to the proximal stomach.
Several past studies have examined QOL after gastric resection; most have important limitations. The largest studies to date have been cross-sectional, assessing QOL in patients from 6 months to 5 years after gastric resection. 5, 6, 8, 9 These well-powered studies concluded that some patients have impaired QOL after curative gastrectomy. Furthermore, the analyses revealed associations between extent of gastric resection (distal compared with total) and QOL on several domains. Although these studies provide important insights into the overall well-being in patients after gastrectomy, they are limited by the lack of baseline QOL assessment. As such, they do not differentiate the extent to which QOL was impaired by the operation as opposed to the underlying disease process. Furthermore, none of these studies reported the QOL data relative to clinically meaningful anchors, so it is difficult for clinicians to discuss the implications of these results with their patients.
Two recent studies have prospectively assessed QOL in patients before and after gastrectomy for cancer using the EORTC modules. Kobayashi et al 7 reported results from 98 patients who had no evidence of recurrence 1 year after gastrectomy. Similar to our results, the authors concluded that QOL worsened in the immediate postoperative period but returned close to baseline by approximately 6 months after operation. The majority of procedures in this study were DG, with only 8 patients undergoing TG, so the authors were unable to make strong conclusions regarding the impact of extent of resection on QOL. In a similar study, Avery et al 4 followed 58 patients who underwent total or subtotal gastrectomy for 2 years after operation. Similar to our findings, their patients had significant deterioration in QOL in the early postoperative period that returned to baseline in most by 6 months. The authors did not explore the impact of extent of resection on QOL because of the limited sample size. This study builds on this prior work by prospectively assessing QOL in a large group of patients undergoing various gastric resections.
This study has several strengths. We enrolled consecutive patients undergoing gastric resection at our institution and prospectively collected QOL data. This allows us to be confident that the results of this study are representative of all patients undergoing gastrectomy at our institution and are generalizable to other institutions that care for similar patients. The inclusion of preoperative QOL data on all patients and the postoperative assessments at fixed times permit comparison between patients, accounting for baseline differences in QOL. Furthermore, because all operations were performed by the same small group of surgeons at 1 institution, it is likely that the differences observed were due to the surgical procedures themselves, rather than differences between surgeons or institutional practices. Importantly, the baseline QOL in these patients was assessed immediately preoperatively--it is likely that many patients already had some impairment from their true, healthy "baseline" as a result of the gastric cancer itself or treatment with neoadjuvant therapy. Therefore, although most patients returned to their preoperative baseline, it is possible that many continued to suffer from important impairment in their QOL.
This study is further strengthened by the use of clinically relevant anchors to interpret the data. In a systematic review of all randomized trials in the field of gastric cancer surgery that reported QOL, all studies reported the results using raw scores and interpreted statistically significant differences as clinically relevant. 19 Few patients or surgeons would be able to discern the extent to which an absolute difference in a QOL measure represents a trivial difference, a small but important difference, or a large difference. As a result, trials that report these raw values are likely to be ignored, or worse, misinterpreted by patients and clinicians. In contrast, we have converted the raw scores into easily interpretable proportions using accepted techniques based upon the MID. 12, 14 Future studies in gastric cancer surgery and beyond should be encouraged to also present their data in ways that are clinically intuitive.
Our study is most limited by missing data. Although we followed patients rigorously, 14% of patients were excluded because of insufficient data and a further 2% were included but had incomplete data. Most of these patients continued to be cared for at our center but chose not to complete the QOL assessments because they found them too burdensome. An additional 33% died during the course of follow-up. We explored several options for controlling for missing data, including various techniques of imputation. Ultimately, we felt that all of these methods suffered from important inherent limitations and the most transparent method of analysis was excluding missing data points from the analysis. It is possible, and perhaps likely, that data were missing in a nonsystematic fashion. For example, patients who died during the study period likely suffered from a worse QOL in the months preceding death relative to patients who did not die during the study period. Unfortunately, this limitation is inherent in all studies of QOL, and it is a particular problem in disease conditions with a significant mortality rate such as gastric cancer. In this study, the mortality rate was similar between the different procedures, making it less likely that data missing due to deaths biased the results.
Although this study identifies important deficiencies in QOL after gastrectomy, the exact etiology of the impairment is not completely clear. It is likely related to a combination of the underlying disease, normal postoperative recovery, and the effect of complications. The extent to which each of these factors contributed to QOL in these patients is unknown. Given the rate of significant complications after gastrectomy (∼15%), this study lacked the power to identify a link between complications and QOL impairment; further research is needed to determine the factors that lead to poor QOL in this patient population. 3 
CONCLUSIONS
In summary, 60% to 70% of patients experience clinically significant deterioration in QOL shortly after gastrectomy. Function and symptoms return to baseline by approximately 6 months postoperatively in most patients, although about a third of patients will continue to have clinically important impairment. Patients who undergo PG suffer from worse reflux, nausea/vomiting, and global QOL compared with patients who undergo DG or TG. Surgeons should discuss expectations regarding symptoms and QOL with their patients before gastrectomy. Alternatives to standard PG should be considered for patients with tumors of the proximal stomach.
